Literature DB >> 29272544

Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience.

Giuseppina Abignano1,2,3, Nafisa Fadl1,2, Mira Merashli1,2, Claire Wenham1,2, Jane Freeston1,2, Dennis McGonagle1,2, Helena Marzo-Ortega1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29272544      PMCID： PMC5850831          DOI： 10.1093/rheumatology/kex454

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  8 in total

1.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

Authors:  William Taylor; Dafna Gladman; Philip Helliwell; Antonio Marchesoni; Philip Mease; Herman Mielants
Journal:  Arthritis Rheum       Date:  2006-08

2.  Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Georg Schett; Jurgen Wollenhaupt; Kim Papp; Rik Joos; Jude F Rodrigues; Adele R Vessey; ChiaChi Hu; Randall Stevens; Kurt L de Vlam
Journal:  Arthritis Rheum       Date:  2012-10

3.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Authors:  C Paul; J Cather; M Gooderham; Y Poulin; U Mrowietz; C Ferrandiz; J Crowley; C Hu; R M Stevens; K Shah; R M Day; G Girolomoni; A B Gottlieb
Journal:  Br J Dermatol       Date:  2015-11-07       Impact factor: 9.302

4.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors:  P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Authors:  Kim Papp; Kristian Reich; Craig L Leonardi; Leon Kircik; Sergio Chimenti; Richard G B Langley; ChiaChi Hu; Randall M Stevens; Robert M Day; Kenneth B Gordon; Neil J Korman; Christopher E M Griffiths
Journal:  J Am Acad Dermatol       Date:  2015-07       Impact factor: 11.527

6.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Authors:  Maurizio Cutolo; Gary E Myerson; Roy M Fleischmann; Frédéric Lioté; Federico Díaz-González; Filip Van den Bosch; Helena Marzo-Ortega; Eugen Feist; Kamal Shah; ChiaChi Hu; Randall M Stevens; Airi Poder
Journal:  J Rheumatol       Date:  2016-07-15       Impact factor: 4.666

7.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103

8.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Authors:  Christopher J Edwards; Francisco J Blanco; Jeffrey Crowley; Charles A Birbara; Janusz Jaworski; Jacob Aelion; Randall M Stevens; Adele Vessey; Xiaojiang Zhan; Paul Bird
Journal:  Ann Rheum Dis       Date:  2016-01-20       Impact factor: 19.103
  8 in total
  4 in total

1.  Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study.

Authors:  Fulvia Ceccarelli; Ramona Lucchetti; Carlo Perricone; Francesca Romana Spinelli; Enrica Cipriano; Simona Truglia; Francesca Miranda; Valeria Riccieri; Manuela Di Franco; Rossana Scrivo; Cristiano Alessandri; Guido Valesini; Fabrizio Conti
Journal:  Clin Rheumatol       Date:  2019-07-17       Impact factor: 2.980

Review 2.  Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors.

Authors:  Gerasimos Evangelatos; Vasiliki Koulouri; Alexios Iliopoulos; George E Fragoulis
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-06-22       Impact factor: 5.346

3.  Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.

Authors:  Matheus Vieira; Solène Buffier; Mathieu Vautier; Alexandre Le Joncour; Yvan Jamilloux; Mathieu Gerfaud-Valentin; Laurence Bouillet; Estibaliz Lazaro; Stéphane Barete; Laurent Misery; Delphine Gobert; Tiphaine Goulenok; Olivier Fain; Karim Sacre; Pascal Sève; Patrice Cacoub; Cloé Comarmond; David Saadoun
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

Review 4.  Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.

Authors:  Andrea Picchianti-Diamanti; Francesca Romana Spinelli; Maria Manuela Rosado; Fabrizio Conti; Bruno Laganà
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.